OTC Triptans in New Zealand

OTC Triptans in New Zealand

In June 2006, sumatriptan was reclassified from a prescription medicine to a restricted medicine (sold by a pharmacist in a pharmacy). This reclassification applied to packs of no more than two 50mg tablets. As a result of this reclassification, three different triptan products were commonly available, Sumagran Active, Imigran and Arrow Sumatriptan. In May 2010, Pharmac announced that it would stop subsidising Imigran and Sumagran Active and begin subsidising Arrow-Sumatriptan by Arrow...

Euromonitor International's OTC Triptans in New Zealand report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors driving growth. Forecasts to 2016 illustrate how the market is set to change.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the OTC Triptans market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market's major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago and Sydney and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

• Headlines
  • Trends
  • Switches
  • Competitive Landscape
  • Prospects
  • Category Data
  • Mylan New Zealand Ltd in Consumer Health (new Zealand)
  • Strategic Direction
  • Key Facts
• Summary 1 Mylan New Zealand Ltd: Key Facts
  • Company Background
  • Production
  • Competitive Positioning
• Summary 2 Mylan New Zealand Ltd: Competitive Position 2011
  • Executive Summary
  • Consumer Health Remains Buoyant During 2011
  • Prevention Remains A Major Focus Area
  • Vitaco Health Continues To Lead Sales
  • Direct Selling Channel Records Growth in 2011
  • Value Sales Expected To Increase Over Forecast Period
  • Key Trends and Developments
  • New Zealand's Ageing Population
  • New Zealand To Be Smoke-free by 2025
  • Natural Health Products Bill
  • Christchurch Earthquake
  • Natural Healing and Prevention
  • Market Indicators
  • Market Data
  • OTC Registration and Classification
  • Vitamins and Dietary Supplements Registration and Classification
  • Advertising
  • Packaging
  • Labelling
  • Distribution
  • Self-medication/self-care and Preventative Medicine
  • Switches
• Summary 3 OTC - Switches 2009-2011
  • Definitions
  • Sources
• Summary 4 Research Sources
• List of Tables
  • Table 1 Sales of OTC Triptans: Value 2007-2011
  • Table 2 Sales of OTC Triptans: % Value Growth 2007-2011
  • Table 3 OTC Triptans Company Shares by Value 2007-2011
  • Table 4 OTC Triptans Brand Shares by Value 2008-2011
  • Table 5 Forecast Sales of OTC Triptans: Value 2011-2016
  • Table 6 Forecast Sales of OTC Triptans: % Value Growth 2011-2016
  • Table 7 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  • Table 8 Life Expectancy at Birth 2006-2011
  • Table 9 Sales of Consumer Health by Category: Value 2006-2011
  • Table 10 Sales of Consumer Health by Category: % Value Growth 2006-2011
  • Table 11 Consumer Health Company Shares 2007-2011
  • Table 12 Consumer Health Brand Shares 2008-2011
  • Table 13 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  • Table 14 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
  • Table 15 Forecast Sales of Consumer Health by Category: Value 2011-2016
  • Table 16 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016